Hospital
Long Beach Memorial Medical
Long Beach Memorial Medical was paid $47.90M by Medicaid between Jan 2018 and Dec 2024, across 360 billing codes. Its largest line is 0450, Emergency room services — 26% of everything it billed.
33Billing provider infoLONG BEACH MEMORIAL MEDICAL
LONG BEACH, CA 90806
LONG BEACH, CA 90806
33aNPI1962442012assigned 06/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$47.90M
24GClaims1,529,649
24DCodes billed360
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#65 of 410
Median peer was paid$6.90M
This provider vs. median6.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 179,480 | $4.83M | |
| 2019 | 153,398 | $4.68M | |
| 2020 | 153,819 | $5.14M | |
| 2021 | 214,507 | $7.04M | |
| 2022 | 286,066 | $9.70M | |
| 2023 | 316,894 | $10.24M | |
| 2024incomplete | 225,485 | $6.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 26% | 188,566 | 172,588 | $12.49M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 6.1% | 20,503 | 19,466 | $2.92M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.9% | 5,296 | 5,124 | $1.85M |
| Z7502 | 3.6% | 45,870 | 45,543 | $1.72M | |
| 99199 | Unlisted special service, procedure or report | 2.6% | 16,896 | 15,533 | $1.26M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 6,479 | 6,231 | $1.25M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.3% | 19,126 | 17,616 | $1.10M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.9% | 36,622 | 32,867 | $930K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.9% | 780 | 772 | $926K |
| 80053 | Comprehensive metabolic panel | 1.8% | 75,746 | 69,739 | $881K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 31,496 | 29,516 | $868K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,436 | 6,253 | $757K |
348 more codes
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 1,887 | $723K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 78,121 | $665K |
| 0949 | 1.4% | 25,222 | $661K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 12,505 | $543K |
| 99285 | Emergency room visit (most serious) | 1.1% | 2,747 | $506K |
| 0270 | 1.0% | 60,513 | $503K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,878 | $447K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,310 | $428K |
| 93975 | <1% | 1,977 | $400K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,407 | $399K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,043 | $353K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,994 | $345K |
| 99283 | Emergency room visit (moderate) | <1% | 5,005 | $334K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,488 | $325K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 9,342 | $303K |
| 99284 | Emergency room visit (serious) | <1% | 3,409 | $302K |
| 76801 | <1% | 4,598 | $297K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,618 | $291K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,408 | $283K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,386 | $281K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,493 | $272K |
| 99221 | <1% | 11,203 | $269K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,777 | $265K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,364 | $242K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,652 | $238K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,434 | $230K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 926 | $228K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,896 | $224K |
| 93976 | <1% | 1,124 | $214K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,275 | $214K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,049 | $213K |
| 95811 | <1% | 949 | $200K | |
| J3490 | Unclassified drugs | <1% | 60,582 | $193K |
| 0360 | <1% | 2,116 | $186K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,784 | $185K |
| 93971 | <1% | 1,608 | $178K | |
| 84484 | <1% | 15,333 | $173K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,043 | $172K |
| 0301 | <1% | 1,651 | $170K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 656 | $153K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,922 | $153K |
| 83690 | <1% | 20,986 | $151K | |
| 0760 | <1% | 6,356 | $144K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,170 | $141K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 2,705 | $140K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,895 | $136K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,630 | $133K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,392 | $129K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,261 | $126K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,903 | $124K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,594 | $123K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 449 | $122K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,900 | $117K |
| 0250 | <1% | 68,883 | $117K | |
| 76642 | <1% | 3,339 | $114K | |
| 81001 | <1% | 31,800 | $107K | |
| 73610 | <1% | 3,551 | $104K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,961 | $103K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 498 | $99K |
| 85730 | <1% | 15,887 | $96K | |
| 83880 | <1% | 3,267 | $95K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,701 | $94K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,982 | $93K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,828 | $92K |
| 90715 | <1% | 2,027 | $92K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 599 | $90K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,719 | $90K |
| 84703 | <1% | 13,945 | $89K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,803 | $86K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,845 | $86K |
| 73630 | <1% | 3,054 | $84K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 480 | $83K |
| 94729 | <1% | 1,815 | $81K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,996 | $79K |
| 97010 | <1% | 2,538 | $76K | |
| 84702 | <1% | 5,649 | $76K | |
| 76770 | <1% | 1,176 | $75K | |
| 93325 | <1% | 661 | $74K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,032 | $74K |
| 94726 | <1% | 1,759 | $73K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,933 | $72K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,975 | $72K |
| 0710 | <1% | 2,669 | $72K | |
| 87486 | <1% | 1,855 | $70K | |
| 93970 | <1% | 423 | $69K | |
| 87581 | <1% | 1,859 | $68K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,871 | $67K |
| 73110 | <1% | 2,258 | $67K | |
| 85610 | <1% | 16,700 | $65K | |
| 73030 | <1% | 2,606 | $65K | |
| 94060 | <1% | 1,754 | $64K | |
| 73562 | <1% | 2,337 | $64K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,177 | $63K |
| 73130 | <1% | 2,193 | $62K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 373 | $62K |
| 77065 | Tomosynthesis, mammo | <1% | 1,416 | $61K |
| 70486 | <1% | 477 | $60K | |
| 85027 | <1% | 10,266 | $60K | |
| Z7610 | <1% | 23,916 | $58K | |
| 93798 | <1% | 2,311 | $58K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,412 | $53K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,229 | $53K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,168 | $53K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,944 | $53K |
| Z7514 | <1% | 901 | $52K | |
| 76536 | <1% | 939 | $52K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,316 | $51K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,093 | $51K |
| 94664 | <1% | 3,607 | $50K | |
| 82947 | <1% | 14,560 | $49K | |
| 80305 | <1% | 3,665 | $49K | |
| 76870 | <1% | 932 | $47K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,612 | $47K |
| 96376 | <1% | 1,587 | $47K | |
| 97116 | <1% | 2,578 | $47K | |
| 0272 | <1% | 6,630 | $44K | |
| 73080 | <1% | 1,404 | $42K | |
| 86923 | <1% | 946 | $42K | |
| 0160 | <1% | 918 | $39K | |
| 73564 | <1% | 1,279 | $39K | |
| 73502 | <1% | 1,151 | $38K | |
| 87186 | <1% | 4,031 | $37K | |
| 87507 | <1% | 89 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,404 | $37K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 893 | $35K |
| 87040 | <1% | 2,494 | $35K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 876 | $34K |
| 86901 | <1% | 9,936 | $34K | |
| 86003 | <1% | 344 | $32K | |
| L3984 | Upper extremity fracture orthosis, wrist, prefabricated, includes fitting and adjustment | <1% | 316 | $30K |
| 93320 | <1% | 421 | $30K | |
| 94010 | <1% | 1,768 | $30K | |
| 86900 | <1% | 9,902 | $30K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,213 | $29K |
| 73590 | <1% | 1,160 | $28K | |
| 81025 | <1% | 5,247 | $28K | |
| 97014 | <1% | 1,395 | $27K | |
| 0720 | <1% | 1,450 | $26K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 280 | $26K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 917 | $26K |
| 83605 | <1% | 2,290 | $26K | |
| 80143 | <1% | 1,276 | $26K | |
| 80179 | <1% | 1,264 | $25K | |
| 73140 | <1% | 1,419 | $25K | |
| 87077 | <1% | 2,787 | $25K | |
| 96417 | <1% | 575 | $25K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,713 | $24K |
| 74018 | <1% | 1,080 | $24K | |
| 80306 | <1% | 1,313 | $23K | |
| 87088 | <1% | 3,143 | $23K | |
| 96367 | <1% | 793 | $22K | |
| 81003 | <1% | 9,373 | $21K | |
| 82803 | <1% | 1,135 | $21K | |
| 86850 | <1% | 4,882 | $21K | |
| 73090 | <1% | 908 | $21K | |
| 85007 | <1% | 6,662 | $20K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 162 | $20K |
| 83735 | <1% | 3,125 | $19K | |
| 72110 | <1% | 590 | $19K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,844 | $19K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,384 | $19K |
| 86140 | <1% | 3,510 | $18K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 143 | $18K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,554 | $18K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,886 | $18K |
| 73560 | <1% | 851 | $18K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,517 | $18K |
| 72100 | <1% | 542 | $17K | |
| 97802 | <1% | 168 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,770 | $16K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 327 | $16K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,177 | $16K |
| 87808 | <1% | 1,578 | $16K | |
| 77336 | <1% | 254 | $15K | |
| 71250 | <1% | 157 | $15K | |
| 0636 | <1% | 2,292 | $14K | |
| 76775 | <1% | 407 | $14K | |
| 36416 | <1% | 4,348 | $13K | |
| 85379 | <1% | 1,097 | $13K | |
| 0300 | <1% | 804 | $12K | |
| 95813 | <1% | 301 | $12K | |
| 80061 | Lipid panel | <1% | 1,112 | $12K |
| J0475 | Injection, baclofen, 10 mg | <1% | 13 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 463 | $11K |
| 84145 | <1% | 530 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 126 | $11K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 353 | $11K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,407 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 186 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,216 | $10K |
| 87070 | <1% | 1,060 | $10K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 359 | $10K |
| 97162 | <1% | 180 | $10K | |
| 97163 | <1% | 124 | $9K | |
| 99070 | <1% | 2,102 | $9K | |
| 71020 | <1% | 251 | $9K | |
| Z7500 | <1% | 259 | $9K | |
| 87147 | <1% | 1,634 | $9K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 280 | $8K |
| 74178 | <1% | 38 | $8K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 683 | $8K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,714 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 206 | $8K |
| 97597 | <1% | 164 | $7K | |
| 87503 | <1% | 281 | $7K | |
| 84100 | <1% | 1,784 | $7K | |
| 72197 | <1% | 30 | $7K | |
| 87210 | <1% | 1,698 | $7K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 657 | $7K |
| 51701 | <1% | 356 | $7K | |
| 87106 | <1% | 236 | $7K | |
| 77080 | <1% | 305 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 212 | $7K |
| 85652 | <1% | 1,979 | $6K | |
| 84439 | <1% | 761 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 964 | $6K |
| 0510 | <1% | 462 | $5K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 551 | $5K |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 158 | $5K |
| 87205 | <1% | 1,185 | $5K | |
| 85384 | <1% | 511 | $5K | |
| 99001 | <1% | 4,580 | $5K | |
| 94618 | <1% | 334 | $4K | |
| 99234 | <1% | 820 | $4K | |
| 0372 | <1% | 92 | $4K | |
| 84460 | <1% | 762 | $4K | |
| 84450 | <1% | 765 | $4K | |
| 12001 | <1% | 292 | $4K | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 390 | $4K |
| 59025 | Fetal non-stress test | <1% | 685 | $4K |
| 12011 | <1% | 212 | $4K | |
| 0761 | <1% | 130 | $4K | |
| 72040 | <1% | 130 | $4K | |
| 74021 | <1% | 129 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 509 | $4K |
| 82150 | <1% | 487 | $4K | |
| 0258 | <1% | 821 | $3K | |
| 73660 | <1% | 195 | $3K | |
| 0361 | <1% | 33 | $3K | |
| 97113 | <1% | 86 | $3K | |
| 82248 | <1% | 584 | $3K | |
| 74183 | <1% | 14 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 572 | $3K |
| 82247 | <1% | 546 | $3K | |
| 82550 | <1% | 397 | $3K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 12 | $3K |
| 97124 | <1% | 103 | $3K | |
| 93017 | <1% | 52 | $3K | |
| 59430 | <1% | 43 | $3K | |
| 96415 | <1% | 82 | $3K | |
| 0324 | <1% | 192 | $3K | |
| 82785 | <1% | 155 | $2K | |
| 82728 | <1% | 192 | $2K | |
| 70360 | <1% | 127 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 294 | $2K |
| 10060 | <1% | 165 | $2K | |
| 0700 | <1% | 72 | $2K | |
| 0750 | <1% | 14 | $2K | |
| 73060 | <1% | 55 | $2K | |
| 90686 | <1% | 85 | $2K | |
| 86592 | <1% | 470 | $2K | |
| 74019 | <1% | 77 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 217 | $2K |
| 88312 | <1% | 156 | $2K | |
| 77334 | <1% | 28 | $2K | |
| 87116 | <1% | 120 | $2K | |
| 75574 | <1% | 13 | $2K | |
| 87102 | <1% | 135 | $2K | |
| 87430 | <1% | 203 | $2K | |
| 95012 | <1% | 72 | $2K | |
| 87081 | <1% | 286 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 82378 | <1% | 89 | $1K | |
| 29125 | <1% | 231 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 256 | $1K |
| 82010 | <1% | 193 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 126 | $1K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $1K |
| 71010 | <1% | 43 | $1K | |
| 81000 | <1% | 495 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 27 | $1K |
| 82330 | <1% | 83 | $1K | |
| 76937 | <1% | 51 | $1K | |
| 87206 | <1% | 166 | $1K | |
| 87015 | <1% | 120 | $1K | |
| 71100 | <1% | 38 | $1K | |
| 72131 | <1% | 12 | $1K | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 2,108 | $996.87 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 262 | $978.66 |
| 0515 | <1% | 40 | $960.79 | |
| 99499 | <1% | 14 | $959.38 | |
| 82784 | <1% | 106 | $936.78 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 308 | $930.04 |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 12 | $924.70 |
| 73552 | <1% | 28 | $914.61 | |
| 72170 | <1% | 41 | $892.88 | |
| 72072 | <1% | 36 | $886.73 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 77 | $872.90 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 26 | $830.26 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 26 | $829.06 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 98 | $721.66 |
| 72050 | <1% | 24 | $696.39 | |
| 85044 | <1% | 254 | $685.32 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 21 | $665.99 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 93 | $638.45 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 40 | $623.22 |
| 84156 | <1% | 221 | $613.59 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 54 | $593.31 |
| 81002 | <1% | 366 | $583.87 | |
| 83550 | <1% | 72 | $523.11 | |
| 92567 | <1% | 18 | $521.90 | |
| 97803 | <1% | 19 | $500.52 | |
| 0401 | <1% | 13 | $500.48 | |
| 83540 | <1% | 85 | $500.01 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 21 | $457.40 |
| 74022 | <1% | 13 | $428.60 | |
| 90656 | <1% | 15 | $406.83 | |
| 86308 | <1% | 70 | $396.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 86 | $395.60 |
| 99000 | <1% | 106 | $393.32 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 17 | $376.87 |
| 83615 | <1% | 74 | $375.62 | |
| 73521 | <1% | 14 | $361.42 | |
| 84132 | <1% | 124 | $360.38 | |
| 0306 | <1% | 128 | $313.22 | |
| 36600 | <1% | 16 | $301.30 | |
| 99401 | <1% | 23 | $301.01 | |
| 90658 | <1% | 17 | $283.53 | |
| 87075 | <1% | 26 | $277.94 | |
| 84481 | <1% | 16 | $251.92 | |
| 91010 | <1% | 13 | $224.85 | |
| 0305 | <1% | 75 | $223.55 | |
| 83520 | <1% | 12 | $212.86 | |
| 87390 | <1% | 12 | $182.21 | |
| 27500 | <1% | 17 | $165.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 58 | $157.45 |
| 85014 | <1% | 77 | $133.89 | |
| 84295 | <1% | 41 | $131.86 | |
| 31720 | <1% | 15 | $127.20 | |
| 86703 | <1% | 12 | $118.73 | |
| 82570 | <1% | 14 | $99.54 | |
| 29515 | <1% | 15 | $80.13 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 22 | $35.06 |
| 84550 | <1% | 12 | $25.51 | |
| 86364 | <1% | 12 | $20.32 | |
| 99072 | <1% | 96 | $8.99 | |
| 0302 | 0% | 31 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFINCH, CHRIS (CHIEF COMPLIANCE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Long Beach Memorial Medical | Long Beach, CA | $21.31M |
| Saddleback Memorial Medical Center | Laguna Hills, CA | $2.89M |
| Long Beach Memorial Medical | Long Beach, CA | $1.89M |
| Long Beach Memorial Medical | Long Beach, CA | $1.09M |
| Long Beach Memorial Medical | Long Beach, CA | $1.04M |
| Long Beach Memorial Medical Center, INC | Long Beach, CA | $802K |
| Long Beach Memorial Medical | Laguna Hills, CA | $1K |
| Long Beach Memorial Medical | Long Beach, CA | $402.67 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.